Streetbeat News

CWBR

CohBar Inc

Employees

Industry

Research and Development in Biotechnology

cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

In Tuesday's after-market session, several healthcare stocks experienced significant movements. 180 Life Sciences (ATNF) saw a 38.2% increase, while GlucoTrack (GCTK) dropped by 15.5%. Other notable gainers include Redhill Biopharma (RDHL), Trinity Biotech (TRIB), Blue Water Biotech (BWV), CohBar (CWBR), and DermTech (DMTK). On the losing side, Better Therapeutics (BTTX), Verve Therapeutics (VERV), Envoy Medical (COCH), Sonnet BioTherapeutics (SONN), and Personalis (PSNL) saw declines in their stock prices.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 9:31 pm

SenesTech, Inc. (NASDAQ:SNES) shares plummeted by approximately 50% after announcing the pricing of a $5.0 million public offering at $1.30 per share with additional warrants. The stock dropped to $0.9189. Other stocks experienced significant movements, with gainers including IceCure Medical Ltd (ICCM), RedHill Biopharma Ltd. (RDHL), and HNR Acquisition Corp (HNRA), among others. Losers included Tharimmune, Inc. (THAR), Cabaletta Bio, Inc. (CABA), and Acelyrin, Inc. (SLRN), with Tharimmune's shares falling sharply after pricing its public offering at $1 per share.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 7:44 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Avidity Biosciences (RNA) led the gainers with a 38.1% increase, while Tharimmune (THAR) saw the largest drop among the losers, falling 69.5%. Other notable movers included Heart Test Laboratories (HSCS), Redhill Biopharma (RDHL), icad (ICAD), and Eiger BioPharmaceuticals (EIGR) with substantial gains, and SenesTech (SNES), CohBar (CWBR), Nexalin Technology (NXL), Better Therapeutics (BTTX), and Altamira Therapeutics (CYTO) with notable losses.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:06 pm

CohBar Inc's (NASDAQ:CWBR) stock price has fallen by 47% after the company received guidance from Nasdaq that its merger agreement with Morphogenesis, Inc would not be approved. Following this, CohBar decided to liquidate and dissolve itself. The company had around $9.1 million in cash, cash equivalents and investments, and approximately $1.5 million in accrued liabilities as of September 30, 2023.

Portfolio Pulse from Henry Khederian

November 01, 2023 | 6:23 pm

The article lists the stocks that gained and lost the most in Wednesday's mid-day session. Notable gainers include Cellectis S.A. (NASDAQ:CLLS) due to strategic collaboration and investment agreements with AstraZeneca, and Patriot Transportation Holding, Inc. (NASDAQ:PATI) due to an acquisition agreement with United Petroleum Transports. Notable losers include WeWork Inc. (NYSE:WE) due to reports of nearing bankruptcy, and Paycom Software, Inc. (NYSE:PAYC) due to worse-than-expected third-quarter sales results and lowered FY23 revenue guidance.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 5:59 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Cellectis (CLLS), Aldeyra Therapeutics (ALDX), Monopar Therapeutics (MNPR), TG Therapeutics (TGTX), Silence Therapeutics (SLN), and Precision BioSciences (DTIL). Losers included CohBar (CWBR), Iridex (IRIX), Kintara Therapeutics (KTRA), Tenon Medical (TNON), G1 Therapeutics (GTHX), and Stevanato Gr (STVN).

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 5:31 pm

CohBar has announced the termination of its merger with Morphogenesis, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 2:45 pm

CohBar has announced its intention to begin the process of liquidating and dissolving itself, according to its organizational documents and applicable law, as per an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:15 pm

CohBar (CWBR) received a termination notice from Morphogenesis on November 1, effectively ending their merger agreement as per the terms outlined in the agreement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:14 pm

CohBar's board has determined that there is no viable path forward to consummate a merger, primarily due to oral guidance received from Nasdaq, according to an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.